Merck & Co., Inc. Payments to Acquire Investments
Merck & Co., Inc. (MRK) reported Payments to Acquire Investments of $522.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-07
- Merck & Co., Inc. payments to acquire investments for the quarter ending 2026-06-30 was $148.00M, a 75.82% decline year-over-year.
- Merck & Co., Inc. payments to acquire investments for the quarter ending 2026-03-31 was $374.00M, a 37.14% decline year-over-year.
- Merck & Co., Inc. payments to acquire investments for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Merck & Co., Inc. payments to acquire investments for the quarter ending 2025-09-30 was $0.00.
- Merck & Co., Inc. payments to acquire investments for fiscal 2025 was $1.21B, a 132.56% increase from fiscal 2024.
- Merck & Co., Inc. payments to acquire investments for fiscal 2024 was $519.00M, a 45.65% decline from fiscal 2023.
- Merck & Co., Inc. payments to acquire investments for fiscal 2023 was $955.00M, a 20.68% decline from fiscal 2022.
- Merck & Co., Inc. payments to acquire investments for fiscal 2022 was $1.20B, a 120300.00% increase from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $148.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $522.00M 10-Q · filed 2026-08-07 | $522.00M derived: sum of 3 quarters · filed 2026-08-07 | $522.00M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $374.00M 10-Q · filed 2026-05-04 | $374.00M derived: sum of 2 quarters · filed 2026-05-04 | $374.00M derived: sum of 3 quarters · filed 2026-05-04 | $986.00M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $612.00M derived: sum of 3 quarters · filed 2026-08-07 | $1.21B 10-K · filed 2026-02-24 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $612.00M derived: sum of 2 quarters · filed 2026-08-07 | $1.21B 10-Q · filed 2025-11-05 | $1.66B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $612.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.21B 10-Q · filed 2026-08-07 | $1.66B derived: sum of 3 quarters · filed 2026-08-07 | $1.66B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $595.00M 10-Q · filed 2026-05-04 | $1.05B derived: sum of 2 quarters · filed 2026-05-04 | $1.05B derived: sum of 3 quarters · filed 2026-05-04 | $1.10B derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $455.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $455.00M derived: sum of 2 quarters · filed 2026-02-24 | $504.00M derived: sum of 3 quarters · filed 2026-02-24 | $519.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $49.00M derived: sum of 2 quarters · filed 2025-11-05 | $64.00M 10-Q · filed 2025-11-05 | $315.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $49.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $64.00M 10-Q · filed 2025-08-05 | $315.00M derived: sum of 3 quarters · filed 2026-02-24 | $432.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $15.00M 10-Q · filed 2025-05-02 | $266.00M derived: sum of 2 quarters · filed 2026-02-24 | $383.00M derived: sum of 3 quarters · filed 2026-02-24 | $408.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $251.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $368.00M derived: sum of 2 quarters · filed 2026-02-24 | $393.00M derived: sum of 3 quarters · filed 2026-02-24 | $955.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | $117.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $142.00M derived: sum of 2 quarters · filed 2024-11-06 | $704.00M 10-Q · filed 2024-11-06 | $1.20B derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $587.00M 10-Q · filed 2024-08-05 | $1.08B derived: sum of 3 quarters · filed 2025-02-25 | |
| 2023-03-31 | $562.00M 10-Q · filed 2024-05-03 | $1.06B derived: sum of 2 quarters · filed 2025-02-25 | ||
| 2022-12-31 | $494.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.20B 10-K · filed 2025-02-25 | ||
| 2022-09-30 | $710.00M 10-Q · filed 2023-11-03 | |||
| 2021-12-31 | $1.00M 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |